Cytomegalovirus (CMV) Antibody, IgG
CMV infection is the most common life-threatening opportunistic infection in immunocompromised patients and neonates. Congenital CMV infection is probably the most common infectious cause of mental retardation and deafness in children. However, the majority of CMV infections in healthy populations remain undetected because most infections with CMV are asymptomatic. Two types of antibodies are produced upon infection with CMV: IgM and IgG. IgM antibodies are present in most individuals within a week or two after the initial exposure and are an indication of acute infection. Eventually, after several months, the level of CMV IgM antibody usually decreases below detectable levels. Additional IgM is produced when latent CMV is reactivated. IgG antibodies are produced by the body several weeks after the initial CMV infection and persist for life. Levels of IgG rise during the active infection then stabilize as the CMV infection resolves and the virus becomes inactive. CMV IgG antibody testing can be used, along with IgM testing, to help confirm the presence of a recent or past CMV infection. Presence of CMV IgG antibody without CMV IgM indicates past infection, whereas presence of CMV IgM and IgG usually indicates acute or persistent infection or reactivation. The presence of IgM alone might indicate exposure or acute infection. Testing for CMV antibody is performed to evaluate immune status to CMV in pregnant women and newborns, in patients prior to organ or bone marrow transplantation, in blood donors, in bone marrow and organ donors and in a person diagnosed with HIV/AIDS. The presence of IgM may indicate current infection, but IgM antibodies may persist for years after initial exposure. False positive IgM antibody may occur due to non-specific binding, antinuclear antibodies, rheumatoid factor, and Epstein-Barr virus infections. IgG antibody titers fluctuate in normal individuals, but a four-fold or greater rise in titer between acute and convalescent sera is indicative of infection.
- Diagnosis of CMV infection
- Evaluation of CMV immune status in transplant patients
- Evaluation of CMV immune status in pregnant women
- Diagnosis of active or reactivated infection in HIV patients
- Assessment of preemptive or prophylactic anti-CMV specific antiviral treatment in transplant patients
- Monitoring response to CMV-specific antiviral therapy
- Diagnosis of CMV infection in newborn and other diseases related to CMV infection in immunocompromised patients
- Assessing CMV status in blood donors
Positive in:
- Past CMV infection, current infection (IgG is positive, IgM might be positive but often negative)
- Recurrent infection (IgG positive, IgM might be positive or negative)
- Acute Infection (IgM positive, IgG might be positive or negative depending on timing)
- Infectious mononucleosis
- Chronic fatigue syndrome
Negative (Non-reactive)
Enzyme immunoassay, ELISA.
Serum (SST) or Plasma (EDTA).
Stability
- Ambient: 3-5 days
- Refrigerated: 5-7 days
- Frozen: 30 day
- Ann Intern Med. 2005;143:870. [PMID: 16365468]
- Transfus Med Rev. 2005;19:181. [PMID: 16010649]
- Transfus Med. 1999 Jun;9(2):115-23. [PMID: 10354380]
- Drew LW. Laboratory Diagnosis of Cytomegalovirus Infection and Disease in Immunocompromised Patients. Curr Opin Infect Dis. 2007; 20:4008-411
- Cytomegalovirus. 2001. Fields Virology. eds. Knipe D, Howley P. Lippincott, Williams and Wilkins, Philadelphia. 2675-2706